Fierce Biotech August 1, 2024
While Biogen’s pharma peers are hunting for late-stage assets with little risk, CEO Chris Viehbacher wants to bring in more early-stage medicines, arguing that there’s more shareholder value to be had the earlier a company can get in.
“One of the things I’d like to see us do is really bring a lot more assets in from an early stage because the earlier you can acquire these assets, the more shareholder value you can create,” Viehbacher said on an earnings call Thursday morning.
Biogen has not been shy about being on the lookout for deals, as Viehbacher oversees a massive pipeline overhaul and internal cost-cutting efforts that began last year. But his suggestion today that he’s open to more risky,...
Today's Sponsors
Today's Sponsor